|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR77 |
Gene summary for WDR77 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR77 | Gene ID | 79084 |
| Gene name | WD repeat domain 77 | |
| Gene Alias | HKMT1069 | |
| Cytomap | 1p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9BQA1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79084 | WDR77 | P130T-E | Human | Esophagus | ESCC | 1.40e-47 | 1.24e+00 | 0.1676 |
| 79084 | WDR77 | HCC1_Meng | Human | Liver | HCC | 4.03e-73 | 3.78e-01 | 0.0246 |
| 79084 | WDR77 | HCC2_Meng | Human | Liver | HCC | 8.36e-09 | 7.13e-02 | 0.0107 |
| 79084 | WDR77 | HCC1 | Human | Liver | HCC | 2.65e-02 | 2.69e+00 | 0.5336 |
| 79084 | WDR77 | HCC2 | Human | Liver | HCC | 5.82e-06 | 2.49e+00 | 0.5341 |
| 79084 | WDR77 | Pt13.b | Human | Liver | HCC | 2.96e-02 | 1.21e-01 | 0.0251 |
| 79084 | WDR77 | S014 | Human | Liver | HCC | 3.39e-40 | 1.19e+00 | 0.2254 |
| 79084 | WDR77 | S015 | Human | Liver | HCC | 2.97e-35 | 1.41e+00 | 0.2375 |
| 79084 | WDR77 | S016 | Human | Liver | HCC | 6.39e-43 | 1.18e+00 | 0.2243 |
| 79084 | WDR77 | S027 | Human | Liver | HCC | 4.28e-09 | 7.73e-01 | 0.2446 |
| 79084 | WDR77 | S028 | Human | Liver | HCC | 1.11e-21 | 9.47e-01 | 0.2503 |
| 79084 | WDR77 | S029 | Human | Liver | HCC | 3.51e-23 | 1.06e+00 | 0.2581 |
| 79084 | WDR77 | C04 | Human | Oral cavity | OSCC | 1.54e-11 | 7.01e-01 | 0.2633 |
| 79084 | WDR77 | C21 | Human | Oral cavity | OSCC | 9.14e-65 | 1.80e+00 | 0.2678 |
| 79084 | WDR77 | C30 | Human | Oral cavity | OSCC | 1.49e-40 | 1.62e+00 | 0.3055 |
| 79084 | WDR77 | C43 | Human | Oral cavity | OSCC | 6.85e-42 | 7.24e-01 | 0.1704 |
| 79084 | WDR77 | C46 | Human | Oral cavity | OSCC | 7.42e-37 | 7.52e-01 | 0.1673 |
| 79084 | WDR77 | C51 | Human | Oral cavity | OSCC | 2.66e-21 | 8.67e-01 | 0.2674 |
| 79084 | WDR77 | C57 | Human | Oral cavity | OSCC | 2.46e-06 | 2.81e-01 | 0.1679 |
| 79084 | WDR77 | C06 | Human | Oral cavity | OSCC | 1.68e-08 | 8.59e-01 | 0.2699 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
| GO:0061458110 | Esophagus | ESCC | reproductive system development | 247/8552 | 427/18723 | 2.24e-07 | 3.42e-06 | 247 |
| GO:004860818 | Esophagus | ESCC | reproductive structure development | 245/8552 | 424/18723 | 2.82e-07 | 4.14e-06 | 245 |
| GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
| GO:00308506 | Esophagus | ESCC | prostate gland development | 32/8552 | 45/18723 | 4.87e-04 | 2.70e-03 | 32 |
| GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
| GO:00016559 | Esophagus | ESCC | urogenital system development | 177/8552 | 338/18723 | 7.51e-03 | 2.69e-02 | 177 |
| GO:004873222 | Liver | HCC | gland development | 242/7958 | 436/18723 | 2.26e-08 | 5.28e-07 | 242 |
| GO:00016553 | Liver | HCC | urogenital system development | 170/7958 | 338/18723 | 2.15e-03 | 1.08e-02 | 170 |
| GO:006145811 | Liver | HCC | reproductive system development | 205/7958 | 427/18723 | 1.16e-02 | 4.27e-02 | 205 |
| GO:004873220 | Oral cavity | OSCC | gland development | 226/7305 | 436/18723 | 2.78e-08 | 5.39e-07 | 226 |
| GO:006145817 | Oral cavity | OSCC | reproductive system development | 217/7305 | 427/18723 | 3.75e-07 | 5.63e-06 | 217 |
| GO:004860816 | Oral cavity | OSCC | reproductive structure development | 214/7305 | 424/18723 | 8.58e-07 | 1.18e-05 | 214 |
| GO:005067310 | Oral cavity | OSCC | epithelial cell proliferation | 212/7305 | 437/18723 | 2.82e-05 | 2.61e-04 | 212 |
| GO:005067810 | Oral cavity | OSCC | regulation of epithelial cell proliferation | 180/7305 | 381/18723 | 5.88e-04 | 3.35e-03 | 180 |
| GO:00016558 | Oral cavity | OSCC | urogenital system development | 160/7305 | 338/18723 | 1.03e-03 | 5.31e-03 | 160 |
| GO:00308505 | Oral cavity | OSCC | prostate gland development | 27/7305 | 45/18723 | 3.49e-03 | 1.47e-02 | 27 |
| GO:0048732110 | Oral cavity | LP | gland development | 149/4623 | 436/18723 | 4.51e-06 | 9.17e-05 | 149 |
| GO:006145818 | Oral cavity | LP | reproductive system development | 128/4623 | 427/18723 | 6.91e-03 | 3.96e-02 | 128 |
| GO:004860817 | Oral cavity | LP | reproductive structure development | 127/4623 | 424/18723 | 7.31e-03 | 4.08e-02 | 127 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR77 | SNV | Missense_Mutation | novel | c.422T>C | p.Val141Ala | p.V141A | Q9BQA1 | protein_coding | tolerated(0.06) | benign(0.08) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WDR77 | SNV | Missense_Mutation | novel | c.754N>A | p.Ala252Thr | p.A252T | Q9BQA1 | protein_coding | tolerated(0.63) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| WDR77 | SNV | Missense_Mutation | novel | c.257N>C | p.Leu86Pro | p.L86P | Q9BQA1 | protein_coding | tolerated(0.18) | possibly_damaging(0.851) | TCGA-A5-A0VQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| WDR77 | SNV | Missense_Mutation | novel | c.344T>C | p.Ile115Thr | p.I115T | Q9BQA1 | protein_coding | tolerated(0.18) | possibly_damaging(0.48) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| WDR77 | SNV | Missense_Mutation | novel | c.289N>A | p.Ala97Thr | p.A97T | Q9BQA1 | protein_coding | deleterious(0.03) | benign(0.232) | TCGA-BG-A220-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WDR77 | SNV | Missense_Mutation | novel | c.186N>T | p.Lys62Asn | p.K62N | Q9BQA1 | protein_coding | tolerated(0.32) | benign(0.212) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| WDR77 | SNV | Missense_Mutation | c.573A>C | p.Arg191Ser | p.R191S | Q9BQA1 | protein_coding | deleterious(0.04) | benign(0.25) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| WDR77 | SNV | Missense_Mutation | novel | c.706A>T | p.Thr236Ser | p.T236S | Q9BQA1 | protein_coding | tolerated(0.71) | benign(0) | TCGA-EC-A1NJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WDR77 | SNV | Missense_Mutation | novel | c.187G>A | p.Asp63Asn | p.D63N | Q9BQA1 | protein_coding | tolerated(0.13) | possibly_damaging(0.589) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| WDR77 | SNV | Missense_Mutation | c.844G>A | p.Val282Met | p.V282M | Q9BQA1 | protein_coding | deleterious(0) | possibly_damaging(0.821) | TCGA-50-5946-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |